

---

	Sylvia Heitzer	CORPORATE COMMUNICATIONS
Phone:	+49 2173 48 1238	Alfred-Nobel-Strasse 10
Fax:	+49 2173 48 1856	40789 Monheim, Germany
E-mail:	<a href="mailto:Sylvia.heitzer@schwarzpharma.com">Sylvia.heitzer@schwarzpharma.com</a>	Internet: <a href="http://www.schwarzpharma.com">www.schwarzpharma.com</a>
Date:	August 27, 2008	

---

## **SCHWARZ PHARMA appoints new CFO**

### **Olaf Elbracht appointed as new Chief Financial Officer of SCHWARZ PHARMA AG.**

August 27, 2008 - The Supervisory Board of SCHWARZ PHARMA AG has appointed Olaf Elbracht as Executive Board member as of September 1, 2008. Within the Executive Board, Olaf Elbracht will serve as Chief Financial Officer (CFO), responsible for Finance, Controlling, Audit and IT.

Since July 1999, Olaf Elbracht is working for the SCHWARZ PHARMA-Group and the UCB-Group respectively. He began his career with the company as Head of Consolidation and Internal/Management Reporting. Two years later he took over the role as Vice President Corporate Finance. In this Function he contributed as core team member to several important projects, among them the integration of SCHWARZ PHARMA in to the UCB-Group. Since September 1, 2007 he is working as Vice President Accounting, Reporting, Consolidation & Shared Services of UCB. Olaf Elbracht will perform his function as CFO of SCHWARZ PHARMA AG in parallel to his current function within UCB, but UCB will release him for the CFO function.

Stephan Röder, Chief Financial Officer since July 13, 2007, will resign at his own request as of August 31, 2008, to meet new challenges. Being exceptionally committed, Stephan Röder has had a decisive part in the success of the SCHWARZ PHARMA group as well as the integration of SCHWARZ PHARMA within the UCB group.

Members of the Executive Board of SCHWARZ PHARMA AG are:

- Peter Möller, CEO
- Olaf Elbracht, CFO
- Prof Dr. Iris Löw-Friedrich, Research & Development
- Simon Looman, Chief Operating Officer
- Martin Schneider, Human Resources

SCHWARZ PHARMA AG (headquartered in Monheim, Germany) is a member of UCB-Group, Brussels, Belgium ([www.ucb-group.com](http://www.ucb-group.com)). UCB is listed on the Euronext Brussels Exchange and owns approx. 89% of the shares of SCHWARZ PHARMA AG.

UCB (Brussels, Belgium) is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing around 11 000 people in over 40 countries, UCB achieved revenue of EUR 3.6 billion in 2007. UCB S.A. is listed on Euronext Brussels.

Contact: Sylvia Heitzer, Tel: +49 2173 48 1238; Antje Witte, Tel.: +32 2 559 9414

Internet: [www.schwarzpharma.com](http://www.schwarzpharma.com)

This press release contains forward-looking statements based on current plans, estimates and beliefs of the management of SCHWARZ PHARMA AG. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation affecting SCHWARZ PHARMA AG, exchange rate fluctuations and hiring and retention of its employees.